Hu’s group reported the orally bioavailable anti-AML PROTAC 51, capable of inducing potent and selective UPS-dependent degradation of FLT3-ITD protein (DC50 of 7.4 nM in MV4-11 cells), with a long-lasting and dose-dependent effect in vitro and in vivo. The gene discussed is FLT3; the disease is acute myeloid leukemia.